

AMENDMENT AND RESPONSE UNDER 37 CFR § 1.116 - EXPEDITED PROCEDURE

Serial Number: 09/702068

Filing Date: October 30, 2000

Title: Enzymatic Treatment of Whey Proteins for the Production of Antihypertensive Peptides and the Resulting Products

Page 3
Dkt: 267.011US1

5. (Currently Amended) An ACE-inhibiting composition as prepared according to claim 1 that comprises a mixture of peptides having the following molecular weight profile, as determined by HPLC

<u>Range (Daltons)</u>	<u>Soluble Peptides</u>
<u>> 5000</u>	<u>50 - 55%</u>
<u>2000 - 5000</u>	<u>15 - 20%</u>
<u>< 2000</u>	<u>30 - 35%</u>

- JBH
4-27-04,
per affy
verification
6. (Currently Amended) ~~(Withdrawn)~~ A treatment regimen for a mammal to inhibit angiotensin-converting enzyme (ACE), said regimen comprising:
orally administering to the mammal, the composition of claim 5 or 32 in amounts and at intervals effective to ~~inhibit~~ reduce ACE activity.

7. (Canceled)

8. (Currently Amended) A The process according to claim 1, wherein said whey protein fraction is a whey protein isolate.

9. (Currently Amended) A The process according to claim 1, wherein said reaction is stopped when the degree of hydrolysis is within the range of from 5.5 to 6.5%.

10. (Currently Amended) A The process according to claim 1, wherein said whey protein fraction is produced by ion exchange and is characterized by a protein content of at least 94% and an ash content of less than 3%.